Results 131 to 140 of about 64,620 (243)

Improving ethnicity data collection and ethnic minority participation in randomised clinical trials [PDF]

UK ethnic minority patients are reported to be under-represented in clinical trials. Under-representation of any patient group within an Randomised Clinical Trial can bias trial results and subsequent extrapolation into the general population. However,
Iqbal, Gulnaz
core  

Population-based characterisation of child and adolescent oral bacterial microbiomes. [PDF]

Microbiome
Wright RJ, DeClercq V, Burton CL, Roslin NM, Chan AWY, Arnold PD, Peters P, Schachar R, Crosbie J, Langille MGI.   +9 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Thinking about ethnicity and gender diversity in children and young people

, 2018
Background:Little is known about how social and cultural variants interact with gender identity development. This article aims to identify the ethnicities of children and young people referred to the United Kingdom’s national Gender Identity Development ...
Hames, Anna, Zitz, Claudia, Manjra, Ilham, de Graaf, Nastasja   +3 more
core   +1 more source

How racial-ethnic, immigration, and 2SLGBTQ+ intersectional self-efficacy of gender-sexuality alliance advisors shapes youth members' positive experiences. [PDF]

J Res Adolesc
Kaufman TML, Kiekens WJ, Di Stasio M, Mascarino A, Marx RA, Poteat VP.   +5 more
europepmc   +1 more source

The quantification and epistemology of medicines use and polypharmacy tested in an observational study

British Journal of Clinical Pharmacology, EarlyView.
Definitions of ‘medicines use’ and ‘polypharmacy’ may refer to all medicines, regular long‐term medicines or another subset. Valid definitions of medicines use should incorporate type of use (long term, short course and as needed [PRN]), changes in use (start, stop and dose change) and a description of temporal examination (cross‐sectional or ...
Lorna Pairman, Paul Chin, Matthew Doogue
wiley   +1 more source

Leading the way: A national mixed-methods survey of race, ethnicity, and gender among gynecologic oncology leaders at ACGME-accredited fellowship programs. [PDF]

Gynecol Oncol Rep
Velasquez J, Gellman C, Wetzler S, Saleh M, Wang K, Blank SV.   +5 more
europepmc   +1 more source

Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications

British Journal of Clinical Pharmacology, EarlyView.
Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba, Mishael Ssesanga, Munir Pirmohamed   +2 more
wiley   +1 more source

North American Genetic Counselors' Perceptions of Identifiability From Demographic Questions on Surveys. [PDF]

J Genet Couns
Ramdaney A, Czerwinski J, Ashfaq M.
europepmc   +1 more source

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source